跳至主要内容
临床试验/EUCTR2013-002245-11-GR
EUCTR2013-002245-11-GR进行中(未招募)1 期

ong-term Follow-up of Subjects With Transfusion-Dependent ß-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

bluebird bio, Inc.0 个研究点目标入组 94 人开始时间: 2020年5月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
94

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Provision of written informed consent for this study by subject, or as applicable, subject’s parent(s)/ legal guardian(s)
  • 2.1. Treated with drug product for therapy of transfusion-dependent ß-thalassemia in a bluebird bio-sponsored clinical study
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 14
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • There are no exclusion criteria for this study.

研究者

相似试验